A Phase1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DUX4 in Adult Patients With Facioscapulohumeral Muscular Dystrophy Type 1
Latest Information Update: 01 Aug 2024
At a glance
- Drugs ARO DUX4 (Primary)
- Indications Facioscapulohumeral muscular dystrophy
- Focus Adverse reactions
- Sponsors Arrowhead Pharmaceuticals
- 05 Mar 2024 Status changed from not yet recruiting to recruiting.
- 02 Feb 2024 Planned initiation date changed from 1 Jan 2024 to 1 Feb 2024.
- 17 Nov 2023 Status changed from planning to not yet recruiting.